Literature DB >> 16531813

Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.

Karin Barbin1, Julia Stieglmaier, Domenica Saul, Kristin Stieglmaier, Bernhard Stockmeyer, Matthias Pfeiffer, Peter Lang, Georg H Fey.   

Abstract

To investigate the influence of N-linked oligosaccharides at asparagines-297 on the cytolytic potential of chimeric CD19 antibodies, three distinct variants were generated by production in different expression systems. The same chimeric CD19 antibody was produced in Sf21 insect cells, human 293 T cells, and 293 T cells expressing a co-transfected beta1,4-N-acetylglucosaminyltransferase III (GnTIII). The N-glycan structures and the cytolytic potential of the antibodies produced in these three systems were directly compared. After expression in insect cells, the antibody carried paucimannosidic N-linked oligosaccharides, distinct from the complex biantennary carbohydrate moieties attached to the product from human cells. After co-expression with GnTIII in human cells, the antibody carried an eightfold greater percentage of oligosaccharides with a bisecting N-acetylglucosamine (78.7% versus 9.6%) and a 30-fold increased proportion of bisecting, defucosylated oligosaccharides (15.9% versus 0.5%). The insect cell product triggered stronger antibody-dependent cellular cytotoxicity (ADCC) of a human leukemia-derived cell line than the product from non-re-engineered 293 T cells and was equally effective at 50- to 100-fold lower concentrations. The antibody from glyco-engineered 293 T cells had comparable lytic activity as the insect cell product. Both mediated significant ADCC at lower effector-to-target cell ratios than the antibody from non-re-engineered 293 T cells, and both were highly effective against primary blasts from pediatric leukemia patients. The data demonstrate the influence of the N-glycosylation pattern on the ADCC activity of chimeric CD19 antibodies and point to the importance of suitable expression systems for the production of highly active therapeutic antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531813     DOI: 10.1097/01.cji.0000175684.28615.7b

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival.

Authors:  Kristel Kodar; Johannes Stadlmann; Kersti Klaamas; Boris Sergeyev; Oleg Kurtenkov
Journal:  Glycoconj J       Date:  2011-12-17       Impact factor: 2.916

Review 2.  Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Authors:  Christian Kellner; Anna Otte; Elisa Cappuzzello; Katja Klausz; Matthias Peipp
Journal:  Transfus Med Hemother       Date:  2017-09-08       Impact factor: 3.747

Review 3.  Protein production from the structural genomics perspective: achievements and future needs.

Authors:  Steven C Almo; Scott J Garforth; Brandan S Hillerich; James D Love; Ronald D Seidel; Stephen K Burley
Journal:  Curr Opin Struct Biol       Date:  2013-05-01       Impact factor: 6.809

4.  Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies.

Authors:  Ursula J E Seidel; Patrick Schlegel; Peter Lang
Journal:  Front Immunol       Date:  2013-03-27       Impact factor: 7.561

Review 5.  IgG-Fc glycoengineering in non-mammalian expression hosts.

Authors:  Andreas Loos; Herta Steinkellner
Journal:  Arch Biochem Biophys       Date:  2012-05-23       Impact factor: 4.013

6.  Intracellular reprogramming of expression, glycosylation, and function of a plant-derived antiviral therapeutic monoclonal antibody.

Authors:  Jeong-Hwan Lee; Da-Young Park; Kyung-Jin Lee; Young-Kwan Kim; Yang-Kang So; Jae-Sung Ryu; Seung-Han Oh; Yeon-Soo Han; Kinarm Ko; Young-Kug Choo; Sung-Joo Park; Robert Brodzik; Kyoung-Ki Lee; Doo-Byoung Oh; Kyung-A Hwang; Hilary Koprowski; Yong Seong Lee; Kisung Ko
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

7.  Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling.

Authors:  Ruihuan Qin; Yupeng Yang; Hao Chen; Wenjun Qin; Jing Han; Yong Gu; Yiqing Pan; Xi Cheng; Junjie Zhao; Xuefei Wang; Shifang Ren; Yihong Sun; Jianxin Gu
Journal:  Clin Proteomics       Date:  2020-02-06       Impact factor: 3.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.